Particle.news

Centre Proposes Separate Licensing For Wholesale Bulk Drugs

The draft creates distinct licence forms and names a competent supervisor to tighten oversight of antimicrobial resistance risks and NDPS diversion.

Overview

  • The Ministry of Health and Family Welfare issued a draft amendment (G.S.R. No. 987 (E)) that separates wholesale licensing for bulk drugs from formulations, a change publicised in national coverage on Thursday, November 19, 2026.
  • The draft adds a new application form (Form 19-BC) and a new licence form (Form 20-BC) specifically for active and inactive bulk substances to make licence records more granular.
  • The rules require sales of bulk drugs to occur under the personal supervision of a named competent person and for licences to list categories of bulk drugs handled, including substances covered by the NDPS Act.
  • The draft is open for a 30-day public consultation with submissions to the Under Secretary (Drugs) in Kartavya Bhawan-1 or by email, after which the ministry may finalise the amendment.
  • Existing wholesalers get a phased transition: the new requirements apply only after their current retention period expires or 12 months after final publication of the amendment, whichever is later, giving firms time to comply.